Bristol Myers Shares New Data on COBENFY for Schizophrenia at Psych Congress, Highlighting Long-Term Safety and Patient Satisfaction
Bristol Myers Shares New Data on COBENFY for Schizophrenia at Psych Congress, Highlighting Long-Term Safety and Patient Satisfaction
Clinical:Bristol Myers Squibb (NYSE:BMY) today announced that new clinical and health economics and outcomes research data (HEOR) from its neuropsychiatry portfolio evaluating COBENFY (xanomeline and trospium chloride) in schizophrenia in adults will be presented at Psych Congress 2024, taking place October 29 – November 2 in Boston, Massachusetts.
Bristol Myers Squibb（紐交所：BMY）今天宣佈，將在2024年的Psych Congress上發佈有關其神經精神病學組合產品COBENFY（曲安脈林和曲斯匹星氯化物）在成人精神分裂症中的臨床和衛生經濟學研究數據（HEOR）。該會議將於10月29日至11月2日在馬薩諸塞州波士頓舉行。
"Building on momentum from the recent U.S. Food and Drug Administration's approval of COBENFY for the treatment of schizophrenia in adults, we're pleased to be sharing additional data at Psych Congress from the EMERGENT clinical trial program that further highlights the differentiated clinical profile of COBENFY, including efficacy, safety, and patient reported outcomes of adults with schizophrenia who participated in our long-term clinical trials," said Alyssa Johnsen, MD, PhD, senior vice president and head of clinical development, Immunology, Cardiovascular and Neuroscience, Bristol Myers Squibb. "As we continue to strengthen our neuropsychiatry portfolio, we remain committed to developing and delivering differentiated options for patients."
"基於最近美國食品藥品監督管理局批准COBENFY用於治療成人精神分裂症的動力，我們很高興在Psych Congress上分享來自EMERGENt臨床試驗項目的額外數據，進一步突出了COBENFY的不同臨床特點，包括成人長期參與我們臨床試驗的精神分裂症患者的療效、安全性和患者報告結果，"Bristol Myers Squibb的免疫學、心血管和神經系統臨床開發負責人Alyssa Johnsen博士說。"隨着我們繼續強化神經精神病學組合產品，我們致力於爲患者開發和提供不同的選擇。"
Research to be presented at the meeting continues to demonstrate COBENFY as a differentiated treatment option for adults living with schizophrenia. Notable data poster presentations include:
將在會議上展示的研究繼續展示COBENFY作爲成人精神分裂症患者的不同治療選擇。值得注意的數據海報展示包括：
Clinical:
臨床：
- Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: Results from the 52-Week, Open-Label EMERGENT-4 Trial
- Long-Term Safety, Tolerability, and Efficacy of Xanomeline and Trospium Chloride in People with Schizophrenia: Results From the 52-Week, Open-Label EMERGENT-5 Trial
- Patient Satisfaction with Xanomeline and Trospium Chloride Treatment for Schizophrenia: A Qualitative Interview-Based Study
- Changes in Quality of Life for Schizophrenia Outpatients Receiving the Muscarinic Agonist Xanomeline and Trospium: Findings of a Qualitative Interview-Based Study
- 精神分裂症中曲安脈林和曲斯匹星氯化物52周開放標籤EMERGENt-4試驗的長期安全性和療效結果
- 精神分裂症患者中曲安脈林和曲斯匹星氯化物52周開放標籤EMERGENt-5試驗的長期安全性、耐受性和療效結果
- 精神分裂症患者對曲安脈林和曲斯匹星氯化物治療的滿意度：基於定性訪談的研究
- 接受肌肉膽鹼激動劑曲安脈林和曲斯匹星氯化物治療的精神分裂症門診患者生活質量的變化：定性訪談研究結果
HEOR:
衛生經濟學團隊：
- Negative symptoms and cognitive impairment in US patients with schizophrenia: a real-world descriptive study using the NeuroBlu database
- Comparative Efficacy, Safety, and Tolerability of Xanomeline and Trospium Chloride versus Eight Atypical Antipsychotics for the Acute Treatment of Adults with Schizophrenia – A Network Meta-Analysis
- Current Estimates of the Incidence and Prevalence of Schizophrenia in the U.S.
- 美國精神分裂症患者的消極症狀和認知障礙：使用NeuroBlu數據庫的實際描述性研究
- 哮喘片和曲斯派柳鹽的比較療效、安全性和耐受性，與八種非典型抗精神病藥物相比，用於成人精神分裂症急性治療-網絡薈萃分析
- 美國精神分裂症發病率和患病率的當前估計
A full list of Bristol Myers Squibb presentations at Psych Congress is below. All presentations will take place in the Exhibit Hall on Thursday, October 31 and Friday, November 1 from 1:30 – 3:00 p.m. ET. For more information, please visit the Psych Congress website here.
在Psych Congress上展示的Bristol Myers Squibb的全部演示在下面。所有演示將於週四，10月31日和週五，11月1日下午1:30至3:00在展廳舉行。欲了解更多信息，請訪問Psych Congress網站。
| Abstract Title | Primary Author | Type |
| Clinical Data | ||
| Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: Results from the 52-Week, Open-Label EMERGENT-4 Trial | Kaul, I. | Poster |
| Long-Term Safety, Tolerability, and Efficacy of Xanomeline and Trospium Chloride in People with Schizophrenia: Results From the 52-Week, Open-Label EMERGENT-5 Trial | Kaul, I. | Poster |
| Patient Satisfaction with Xanomeline and Trospium Chloride Treatment for Schizophrenia: A Qualitative Interview-Based Study | Horan, W. | Poster |
| Changes in Quality of Life for Schizophrenia Outpatients Receiving the Muscarinic Agonist Xanomeline and Trospium: Findings of a Qualitative Interview-Based Study | Weiden, P. | Poster |
| Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: Post Hoc Analyses of Data Pooled From Three 5-Week, Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials | Kaul, I. | Poster |
| Xanomeline and Trospium Chloride for the Treatment of Agitation in Schizophrenia: PANSS-EC Results From Three Randomized, Double-Blind, Placebo-Controlled Trials | Yeung, P. | Poster |
| Long-Term Metabolic Outcomes Associated With Xanomeline and Trospium Chloride: Interim Results From Pooled, Long-Term Safety Studies EMERGENT-4 and EMERGENT-5 | Claxton, A. | Poster |
| Assessing Participant Experience With Xanomeline and Trospium Chloride Treatment Using In-Trial Qualitative Interviews: Perceived Effect on Symptoms During a Long-Term Phase 3 Trial in Schizophrenia | Horan, W. | Poster |
| Health Economics and Outcomes Research | ||
| Negative symptoms and cognitive impairment in US patients with schizophrenia: a real-world descriptive study using the NeuroBlu database | Lipunova, N., Holmusk Technologies, Inc. | Poster |
| Comparative Efficacy, Safety, and Tolerability of Xanomeline and Trospium Chloride versus Eight Atypical Antipsychotics for the Acute Treatment of Adults with Schizophrenia – A Network Meta-Analysis | Hickey, C., Lumanity | Poster |
| Current Estimates of the Incidence and Prevalence of Schizophrenia in the U.S. | Cajigal, A. | Poster |
| 摘要標題 | 主要作者 | 類型 |
| 我們相信，總的來說，儘管迄今爲止公開的ReDiscover試驗的中期臨床數據是初步的，但數據支持不同劑量的有選擇性靶點的作用。 | ||
| 在精神分裂症患者中的氨麻醯胺和特羅斯匹克長期安全性和有效性：來自爲期52周的開放標籤EMERGENt-4試驗的結果 | 考爾，艾. | 海報 |
| 精神分裂症患者中氨麻醯胺和特羅斯匹克長期安全性、耐受性和有效性：來自爲期52周的開放標籤EMERGENt-5試驗的結果 | 考爾，艾. | 海報 |
| 患有精神分裂症的患者對氨麻醯胺和特羅斯匹克治療的滿意度：基於定性訪談的研究 | Horan, W. | 海報 |
| 接受Xanomeline和Trospium的精神分裂症門診患者生活質量變化：定性訪談研究結果 | Weiden, P. | 海報 |
| Xanomeline和Trospium氯化物在精神分裂症中的功效：來自三項5周，隨機，雙盲，安慰劑對照的EMERGENt試驗數據的事後分析 | Kaul, I. | 海報 |
| Xanomeline和Trospium Chloride用於治療精神分裂症激動狀態：三項隨機、雙盲、安慰劑對照試驗的PANSS-EC結果 | Yeung, P. | 海報 |
| 與Xanomeline和Trospium Chloride相關的長期代謝結果：來自彙總的長期安全性研究EMERGENt-4和EMERGENt-5的臨時結果 | Claxton, A. | 海報 |
| 使用Xanomeline和Trospium Chloride治療評估參與者經驗：在精神分裂症第3期長期試驗期間的定性訪談中對症狀產生的感知影響 | Horan, W. | 海報 |
| 健康經濟與結果研究 | ||
| 在美國患有精神分裂症的患者中負性症狀和認知障礙：使用NeuroBlu數據庫進行的現實世界描述性研究 | Lipunova, N., Holmusk Technologies, Inc. | 海報 |
| 對氧安默啶和託斯匹克氯化物與八種非典型抗精神病藥物在急性治療成年精神分裂症患者中的比較療效、安全性和耐受性進行的網絡薈萃分析 | Hickey, C., Lumanity | 海報 |
| 美國精神分裂症患病率和患病率的當前估計。 | Cajigal，A。 | 海報 |
譯文內容由第三人軟體翻譯。
